Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 69Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 38Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Myelodysplastic Syndromes 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 15Radiotherapy 14Specimen Handling 13Radiation 9Biopsy 5pembrolizumab 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Bevacizumab 4vorasidenib 3trametinib 3Surgical Procedures, Operative 3Spinal Puncture 3tovorafenib 2dabrafenib 2Restraint, Physical 2Leukapheresis 2Ipilimumab 2Genetic Therapy 2Fluorodeoxyglucose F18 2Eflornithine 2Craniotomy 2Carboplatin 214-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 2vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tozuleristide 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Astrocytoma × Ipilimumab × 1 year × Clear all
NCT04145115 2026-05-29

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled
CNS

Astrocytoma, Glioblastoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡